Flagship · Weekly Brief

Macro rationale

Stagflation prints (CPI 3.8% YoY, NFP +115k, U-6 8.2%, ISM Prices Paid 84.6) collide with extreme financial complacency (HY OAS 2.72%, VIX 15.33, S&P 21x fwd, QQQ +19.5% above 200d with wRSI 77.2). Warsh-led Fed locked into hawkish hold with 10Y at 4.45%; BOJ June 16-17 hike likely accelerates yen carry unwind. Pillar tilts per brief §1.1: overweight Energy/Defense to physical inelasticity (DAWG $54.6B, uranium spot $86 = LT contract, hyperscaler nuclear PPAs); underweight Compute/Biology duration. Cash held at top of neutral band (13.9%) as tactical reload reserve — VIX convexity historically cheap but I'm executing equity-side defensiveness via mid-cap rotation rather than vol. Anchor list (TSM, CCJ, VRTX, plus HEI promoted; LLY retired to satellite) unchanged in posture; brief's hyperscaler component-cost tax (MSFT noted $25B of $190B capex is pure inflation) hardens conviction in the pricing-power layer (TSM, BWXT, FN) over the model-builders.

Thesis

Two broken-thesis closes via unlock path B: AVAV (multiple securities class actions filed re: SCAR competition misrepresentation, briefer verdict=broken, score 46) and TLN (score 44 on first journal entry, below 60 floor, nuclear sector reflexive selloff, debt issuance leverage risk). Capital redeploys into three named-flow mid-caps the brief explicitly cites or that pass the conviction-per-dollar test: FN (Fabrinet — AWS optical transceiver monopoly, $872M Q3 rev +19% YoY, brief §7.1), BWXT (Navy nuclear monopoly, $1.4B propulsion contract + Project Pele microreactor, brief §7.3), MRCY (DoD space/strategic weapons $60M+ Jan 2026 awards, $1.5B backlog, book-to-bill 1.23). Modest trims to non-locked weakeners: NVDA -2pp (China export loophole closure), CCJ -2pp (score -13 drift, weight runaway), AVGO -1.31pp (score 61 one point above broken). Within-lock 2pp trim on BE (score 43, drift overweight). Adds to anchors TSM +1pp (only intact compute, score 83) and VRTX +1pp (only intact biology, score 76, brief §5.4 commercial-stage criterion met). Three commodity-producer tail hedges retained (CCJ, SCCO, MP). 19 positions, 13.9% cash.

Reflection

Brief mandates Energy/Defense overweight to physical inelasticity; clean broken-thesis closes (AVAV litigation, TLN sub-60) fund three mid-cap displacers (FN, BWXT, MRCY) named or adjacent to brief §7

The conviction lock is doing exactly what it's supposed to — most of the 5/27 mid-cap opens (BE, MP, KTOS, SCCO) are showing weakness or score gaps but I can't react past 2pp without an unlock path, which forces me to actually evaluate whether the original thesis is still intact rather than whipsawing on price. BE and KTOS are the uncomfortable cases: both have weight-drift problems and softening flow but the underlying named contracts (Brookfield $5B, MACH-TB $1.45B) haven't been amended. I'm trimming BE to 1.78% as a within-lock action but holding KTOS — the catalyst misalignment (Trump FPV

Positions (19)

• NVDANVIDIAcompute

  trim5.69%-2.00pp72
  flow softeningconf

  Funder

  Hyperscaler 2026 capex anchored on Blackwell/H200: MSFT $190B, AMZN $200B, GOOGL $180-190B, META $125-145B — ~$725B aggregate per brief §5.1. Stargate $500B JV NVDA-hardware anchored. Norway GPFG and GIC added through 2024 13F cycle. Iren neocloud deal confirms domestic demand.

  Unwind

  Trim driver: Commerce closed overseas-routing loophole that funneled NVDA chips to China — direct revenue channel impairment not priced at entry. Score -16 to 72. Further unwind if hyperscaler 2027 capex guidance revised down >15% or DC revenue growth breaks below 30% YoY.

  Catalyst

  NVDA earnings late Aug 2026; June US-China summit on $30B reciprocal tariff framework

• TSMTaiwan Semiconductor Manufacturingcompute

  hold8.31%83
  flow acceleratingconf

  Funder

  Only intact compute name (score 83, drift +1). Jensen named $150B/yr Taiwan AI hub investment; CHIPS Act $6.6B Arizona disbursement locked. NVDA/AMD/AAPL/AVGO leading-edge silicon flows exclusively through TSMC sub-3nm nodes. Top tech fund holds at 14.4% concentration. Sustained >50% gross margin.

  Unwind

  Intel 18A wins second hyperscaler accelerator program (currently zero), or Samsung sub-2nm yield closes to <5pp gap. CHIPS Act repealed or Arizona disbursement clawed back. Norway GPFG net trims ≥25%.

  Catalyst

  July 2026 monthly revenue prints; CoWoS capacity expansion update

• ASMLASML Holdingcompute

  hold2.48%64
  flow softeningconf

  Funder

  EUV monopoly intact at trimmed weight; Coatue Q1 add affirms thesis. Norway GPFG holds. ASML 2030 guidance anchors long-cycle thesis. TSMC/Samsung/SMIC 2025-27 EUV orderbook backstops cash flow despite -21pt score drift.

  Unwind

  China domestic EUV alternative reaches commercial-scale wafer output (currently aspirational per 5/28 news), or book-to-bill prints <0.9 for two consecutive quarters. Coatue trims >25%.

  Catalyst

  July 2026 Q2 earnings + book-to-bill disclosure

• AVGOBroadcomcompute

  trim1.75%-1.31pp61
  flow softeningconf

  Funder

  Hyperscaler custom-silicon contracts: GOOG TPU multi-gen, META MTIA, Anthropic 3.5GW. Hock Tan named >$25B AI revenue trajectory FY26. Tiger Global increased stake (5/28). VMware integration cash flow funds $7B+ annual buyback.

  Unwind

  Score now 61 — one point above broken floor. Custom silicon FY26 revenue guidance below $25B, or hyperscaler ASIC program loss to in-house silicon team. June 3 earnings is the binary catalyst.

  Catalyst

  June 3 2026 Q2 earnings report

• MUMicron Technologycompute

  hold2.48%77
  flow steadyconf

  Funder

  HBM3e/HBM4 capacity sold out through 2026; UBS PT to $1,650 on memory boom. Big-tech capex through 2027 underpins HBM ramp. Stock crossed $1T market cap on AI memory demand. Score 77, drift 0. Within 25-day conviction lock.

  Unwind

  HBM allocation share lost to SK Hynix below 30%, or hyperscaler memory commitments slip from 2026 to 2027. NAND ASP collapse >20% sequential.

  Catalyst

  Late June FQ3 earnings

• CCJCamecoenergy

  trim8.71%-2.00pp65
  flow steadyconf

  Funder

  Saskatchewan provincial backstop; Westinghouse 49% JV with Brookfield; long-term utility uranium contract book at $60+/lb with term-market spiking to ~$93/lb per brief §5.2. Kazatomprom 8Mlb output cut maintains structural deficit through 2028. 75 reactors under construction globally. Q1 EPS +88%.

  Unwind

  Trim driver: score -13pt drift to 65 + weight runaway to ~12% live via passive appreciation. Further unwind if U3O8 spot rolls below $70/lb or Westinghouse JV monetization stalls.

  Catalyst

  Q2 earnings late July; uranium spot trajectory into Q3

• GEVGE Vernovaenergy

  hold7.11%63
  flow steadyconf

  Funder

  H-class turbine fleet 4M operating hours (128 units, 74GW), $150B+ backlog sold out through 2028. 100 GW gas turbine backlog Q1 2026 per brief §5.2 with 10-20% price realization growth. AI data-center grid pull-through. Norway GPFG added post-spin. IRA transmission/grid grants flowing.

  Unwind

  Score sits 3pts above 60 floor — next order-book disclosure must confirm backlog growth. Backlog falls >10% sequentially or H-class delivery slippage. IRA transmission tax credits repealed.

  Catalyst

  Q2 earnings late July; FY27 backlog guidance

• BEenergy

  trim2.09%-2.00pp43
  flow steadyconf

  Funder

  Brookfield $5B AI data-center fuel-cell partnership (Oct 2025); Oracle on-site DC power agreement with warrant for 3.53M shares; record $6B product backlog tied to AI infra; Nebius partnership (5/28). Capacity doubling to 2GW annual. Q1 2026 revenue +130% YoY.

  Unwind

  Within-lock 2pp trim: score 43 below 60 floor, weight drift to ~10% live, valuation stretched (+1,400% 12mo). Further unwind only on unlock path: Brookfield or Oracle agreement amended/cancelled, or backlog drops >25%.

  Catalyst

  Q2 earnings early August

• MPMP Materialsenergy

  hold4.74%
  flow steadyconf

  Funder

  DoD $400M Series A Preferred (Jul 2025) + up to $350M additional + $150M DoD loan for heavy rare earth separation. 10-year NdPr price floor and 10-year magnet offtake commitment for 10X Facility. China rare earth magnet 98% control creates 2027 supply deadline (per NOC briefing). Brief §7.3 mid-cap candidate adjacent.

  Unwind

  DoD preferred conversion or offtake amendment, NdPr price floor breached. Magnet ramp slips past Q4 2026. Within-lock — any further trim requires unlock path.

  Catalyst

  Q2 magnet production ramp milestones; DoD offtake disclosures

• SCCOSouthern Copperenergy

  hold4.74%63
  flow steadyconf

  Funder

  Copper $6.50+/lb ATH in Jan 2026; BHP results confirm copper margin leadership. AI/data-center demand 30% of new copper demand by 2030 per BloombergNEF. Tia Maria and Los Chancas project additions. Mexican gov dividend signal. Tail-risk commodity-producer hedge slot per §5.3. Score stable 63, drift 0.

  Unwind

  Copper falls below $5/lb sustained, or Tia Maria/Los Chancas permit revoked. Mexican fiscal reform raises producer royalty >5pp. Grupo Mexico parent action redirects cash.

  Catalyst

  Q2 earnings late July; copper price trajectory through Q3

• KTOSKratos Defensedefense

  hold9.78%
  flow steadyconf

  Funder

  DoD MACH-TB 2.0 IDIQ prime $1.45B ceiling 5yr (Jan 2025); DoD Industrial Base Project Helios hypersonic materials $68.3M single-award (Oct 2025); USMC XQ-58A Valkyrie MUX TACAIR $34.8M mod; C5ISR hardware $30M+. DAWG-adjacent. Brief §5.3 autonomous-systems theme. Within 25-day lock.

  Unwind

  FY27 DAWG budget sequestered, MACH-TB task orders fail to materialize at $200M+/yr run rate. Trump drone subsidies confirmed FPV-only and exclude Valkyrie/Mako (5/29 flag noted but not confirmed). Within-lock; close requires unlock path.

  Catalyst

  FY27 DoD budget markup; Q2 earnings

• HEIHEICOdefense

  hold7.82%68
  flow steadyconf

  Funder

  Defense aftermarket compounder — Mendelson family owners since 1957, 20%+ FCF CAGR. Q2 beat: FSG $929M vs $864M consensus, ETG $460M vs $396M. Wencor integration accretive. Acquisition tape adding $1B+ revenue annually. NDAA mandatory funding + commercial aerospace MRO duopoly tailwind. Score 68, drift 0.

  Unwind

  Mendelson family stake sold or insider cluster reverses. Commercial aerospace MRO cycle inverts (post-Boeing 737MAX delivery normalization). M&A cadence drops below $500M/yr.

  Catalyst

  Q3 earnings late August

• LLYEli Lillybiology

  hold2.85%70
  flow softeningconf

  Funder

  Mounjaro/Zepbound franchise compounding internationally; retatrutide Phase 3 28-30% body-weight loss leapfrogs semaglutide and frames multi-decade franchise (5/30). Curevo $1.5B + LimmaTech acquisitions extend vaccine/ID portfolio. Norway GPFG and large AM holders. Trump Q1 13F loaded additional LLY (5/28 haiku flag).

  Unwind

  Oral GLP-1 entrants (NVO oral Wegovy, VKTX) take US script share >15%. Retatrutide CV outcomes miss. Norway GPFG trims >25%. Medicare GLP-1 price negotiation cuts US revenue >20%.

  Catalyst

  Q2 earnings late July; retatrutide CV outcome readout

• VRTXVertex Pharmaceuticalsbiology

  hold3.55%76
  flow steadyconf

  Funder

  Only intact biology score (76, drift -2). Casgevy partnership with CRISPR expanding to pediatric populations; suzetrigine non-opioid pain launch tracking; CTX611 anticoagulant ($20B TAM) trial data upcoming. Self-funded cash runway insulates from 4.45% yield duration trap per brief §5.4 commercial-stage-only criterion. Mature CF franchise still cash-generative.

  Unwind

  Suzetrigine launch traction disappoints (scripts <50k/quarter by Q4 2026), or Casgevy reimbursement coverage fails to expand. CF franchise revenue declines >15% YoY. CTX611 Phase 2 readout misses.

  Catalyst

  CTX611 anticoagulant trial readout; suzetrigine launch update

• NVONovo Nordiskbiology

  hold1.66%67
  flow softeningconf

  Funder

  Wegovy/Ozempic franchise cash-generative; Novo Holdings sovereign-style ownership backstop. Norway GPFG and large EU pension funds hold. Oral Wegovy differentiator vs LLY injectable at cheaper 37x P/E. CagriSema next-gen pipeline.

  Unwind

  Retatrutide takes US obesity share >15% in 2026. CagriSema readout disappoints vs LLY benchmarks. Novo Holdings reduces strategic stake. Generic Wegovy in India accelerates margin erosion (5/27 flag).

  Catalyst

  CagriSema Phase 3 readout; Q2 earnings

• ARGXargenxbiology

  hold1.43%71
  flow acceleratingconf

  Funder

  FDA expanded Vyvgart/Hytrulo approval to all gMG serotypes including seronegative (5/28-29 — 18% TAM expansion). Market projected $6B→$16B by 2036. Pipeline: CIDP, MMN, SjD label expansion ongoing. Multi-billion peak sales trajectory. Score 71, drift 0. Within 25-day lock. Brief §5.4 commercial-stage criterion met.

  Unwind

  Vyvgart CIDP Phase 3 readout misses, or US payer coverage restricts seronegative gMG patients. Argenx Holdings stake sold. Competitor (UCB rozanolixizumab) takes >20% market share.

  Catalyst

  June investor conferences; CIDP launch traction Q2 prints

• FNcompute

  hold3.93%63
  flow acceleratingconf

  Funder

  Brief §7.1 explicit mid-cap candidate. AWS hyperscaler is dominant customer driving 35.9% YoY revenue growth prior Q; Q3 FY26 total revenue $872M (+19% YoY). 800G/1.6T optical transceiver demand from Nvidia/AMD GPU clusters. Extracts hyperscaler CapEx wave without absorbing component-inflation tax that hits hyperscalers and model-builders. $24.6B mcap — mid-cap displacement.

  Unwind

  Datacom segment sequential decline >5%, or AWS signals pivot to in-house optical manufacturing (per brief §7.1 unwind). 800G design loss to Coherent or Lumentum.

  Catalyst

  FY26 Q4 earnings August; AWS re:Invent capex commentary

• BWXTBWX Technologiesenergy

  hold5.88%55
  flow acceleratingconf

  Funder

  Brief §7.3 explicit mid-cap candidate. Monopoly Naval Nuclear Propulsion reactor manufacturer — $1.4B propulsion contracts recently awarded. Project Pele microreactor fully DoD-funded. Precision Custom Components acquisition adds heavy manufacturing for commercial SMR wave (hyperscaler PPAs). NRC Part 53 final rule (Mar 25 2026) accelerates SMR licensing. $18.6B mcap. Dual-pillar exposure energy+d

  Unwind

  Project Pele fails NRC/DOE authorization basis. Navy Columbia-class delivery schedule slips materially. SMR commercial orders (X-energy, Kairos) cancelled or deferred past 2028.

  Catalyst

  Q2 earnings early August; Project Pele construction milestone

• MRCYcompute

  hold3.06%
  flow acceleratingconf

  Funder

  Discovery-agent flow_score 100. DoD space and strategic weapons contracts >$60M (Jan 2026): radiation-hardened signal processing program extension through 2031, national security space program production contract. Multi-year cost-plus-fixed-fee multi-domain subsystem development contract (Sep 2025). $12.3M avionics CMU contract. Record $1.5B backlog; book-to-bill 1.23. Mid-cap displacement for DAW

  Unwind

  Book-to-bill falls below 1.0 for two consecutive quarters. Space Force OPIR/Golden Dome program reallocations cut Mercury subsystem content. Free cash flow remains negative through FY27.

  Catalyst

  FQ4 earnings August; FY27 DoD budget markup

Warnings

• stale_policy guard: TSM add → hold (delta zeroed)
• stale_policy guard: VRTX add → hold (delta zeroed)
• stale_policy guard: FN open → hold (delta zeroed)
• stale_policy guard: BWXT open → hold (delta zeroed)
• stale_policy guard: MRCY open → hold (delta zeroed)
• open_universe: BWXT already on watchlist — dropped
• open_universe: MRCY score=53 < 60 — dropped
• ledger stale (one or more positions had no last_price) — rebalance diffed against intent

Conviction-lock actions

1. Turn 1ConvictionGuard (§6.5d)

   —
2. Turn 2ConvictionGuard (§6.5d)

   —

Cost breakdown

Per-call cost computed from cost.js pricing constants (Opus 4.7, Sonnet 4.6, Haiku 4.5). Cache-read tokens billed at 10% of input. See Cost & ROI for the rolling 30-day ledger.